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Abstract: 
Literature shows that various molecular cascades are activated by stress, UV rays and pollutants leading to wrinkle formation of the skin. These 
cascades start from five types of receptors (EGFR, PDGFR, PAFR, IL1R, TNFRB) and terminate with the production of matrix 
metalloproteinase’s, which degrades collagen leading to wrinkle formation. Signaling pathway leading to wrinkle formation showed that c-jun is 
involved in these cascades. Therefore, c-jun is the preferential choice for inhibition to reduce the intensity of collagen degradation. Hence, the 3D 
structure of c-jun was modeled using segment based homology modeling by MODELLER 9v5. Evaluation of the constructed model was done by 
PROCHECK, WHAT CHECK and through RMSD/RMSF calculations. Ligands for the inhibitory sites were designed using LIGANDSCOUT. 
The interaction study of ligand and receptor was performed by AUTODOCK. A library of analogues was constructed for three known inhibitory 
sites. The receptor-analogue study was performed using the software MOLEGRO Virtual Docker. The analogues constructed from the designed 
novel reference ligands showed good binding with the receptor binding sites. It should be noted that these predicted data should be validated 
using suitable assays for further consideration. 
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Background: 
Skin ageing is a hot research topic. Skin research has led to the 
development many products to keep skin younger and healthier for a 
long period. There are many preparations like Botox injections, laser 
treatment, fat graft implantation, etc., for skin ageing. However, these 
products are often expensive and usually have side effects. Hence, 
there is a need to analyze the molecular pathways for skin ageing and 
to inhibit potential targets. There are various symptoms for skin ageing 
but one of the most prominent sign of skin ageing is wrinkle 
formation. Wrinkle appears on the skin both due to intrinsic and 
chronological skin ageing (occurs with the passage of time) and 
premature skin ageing (influence of external factors like UV rays, 
stress and pollution). Data suggest that there are five receptors (EGFR, 
PDGFR, PAFR, IL1R and TNFRB) that are activated by stress. They 
stimulate their corresponding adapter proteins, mitogen activated 
protein kinases (MAPKs) and transfer the signal down to the nucleus 
to transcription factor activation protein 1 (AP-1). AP-1 further 
induces the transcription of matrix metalloproteinase’s (MMPs).  
 
MMPs(1,3,9) degrade collagen. The excessive degradation of collagen 
leads to loss of skin integrity towards wrinkle formation. Signaling 
cascade studies show that EGFR, PDGFR and PAFR through MAPK1 
bring activation of AP-1. TNFRB through MAPK9 and IL1R through 
MAPK8 activation of AP-1 are known. However, different MAPKs 
were involved leading to activation of AP-1.  Hence, if collagen 
degradation, activated by different stressors through different receptors 
is to be inhibited; AP-1 should be targeted [1]. AP-1 is made up of two 
subunits, namely c-fos and c-jun. It is known that c-jun expression is 
limiting AP-1 activation in human skin as c-fos concentration is 
constant, while c-jun concentration increases in photo-aged skin and 
old skin [2]. Moreover, c-fos-regulated genes exert a protective
 
function and its deficiency makes the cells hypersensitive
 to a broad 
spectrum of DNA-damaging agents. Therefore, c-jun is a preferential 
choice for inhibition. c-jun is 331 residues long. It consists of a leucine 
zipper domain and a basic region. c-jun interacts with DNA by the 
leucine zipper domain.  
 
In c-jun, the transcription activation domain residues are 91-186, the 
transcription repression domain residues are 31-57 and the promoter 
region for T antigen-dependent DNA unwinding (required for the 
initiation of polyoma virus DNA replication) residues are 91-186. The 
region 241- 252 residues of c-jun can increase DNA bending and 
binding at the AP-1 site [3]. Residues 252-281 in c-jun are the basic 
sub-domain, which is responsible for the sequence specific recognition 
site of DNA [4]. Studies performed so far have targeted MAPKs to 
inhibit the activation of c-jun. It has been shown that three types of 
MAPK are involved in collagen degradation. Therefore, to completely 
inhibit the degradation of collagen (wrinkle formation) activated by 
various stressors, c-jun is targeted. However, the complete structure 
for c-jun is still not available for inhibitor design. Therefore, 
homology modeling is performed to construct the 3D structure for c-
jun followed by inhibitor design through docking.  
 
Methodology: 
Homology modeling: 
3D structure modeling is the first step towards successful in silico drug 
designing. A suitable template with sufficient query sequence length 
coverage and sequence identity is not as yet available. Therefore, 
segment based homology modeling approach is used in this study. 
Fold recognition was employed for loop modeling in this procedure. 
BLAST and PSI BLAST were used for the selection of PDB templates 
and templates with > 40% sequence identity with the target sequence 
were selected (Table 1 in supplementary material). LOMETS (Local 
Meta Threading Server) was used to select templates for loop 
modeling. The server selects fold not only on the basis of secondary 
structure but also considers mutations, solvent accessibility and 
pairwise residue contacts [5]. Subsequently, the target sequence and 
templates were aligned using MODELLER 9v5 and thus, a 3D model 
was constructed. The constructed model was energy minimized in 
GROMACS force field using Steepest Descent Minimization 
Algorithms. The model was evaluated using PROCHECK, WHAT 
CHECK and RMSD, RMSF calculations. RMSD and RMSF 
calculations are good indicators of the uncertainty in the atomic 
coordinates and the favorable value is within 0.2 nm. PROCHECK 
validates the model for covalent bond distances, angles, atom 
nomenclature and stereo-chemistry [6]. What-check was used to 
evaluate the folding pattern of the model [7]. 
 
Ligand and receptor interaction: 
Inhibitors are not yet available for c-jun. Therefore, it is important to 
design suitable inhibitors for c-jun. Ligands were designed using 
LIGAND SCOUT 2.02. The designed ligand and receptor interaction 
at desired position are performed using AUTODOCK version 1.5.2. 
Ligand analogues have been constructed using CHEMSKETCH and 
docking was performed by Molegro Virtual Docker (MVD). We used 
MVD because it showed higher docking accuracy than other state-of-
the-art docking products (MVD: 87%, Glide: 82%, Surflex: 75%, 
FlexX: 58%) in the market [8]. During virtual screening, the following 
parameters were fixed: number of runs 10, population size 50, 
crossover rate 0.9, scaling factor 0.5, maximum iteration 2,000 and 
grid resolution 0.30. The docked results were evaluated on the basis of 
binding affinity, moledock score and re-ranking. Binding affinity Bioinformation   open access 
www.bioinformation.net    Hypothesis
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(kg/mol) is measured on the basis of known experimental data. The 
MolDock scoring function takes into consideration directional 
hydrogen bonding and charges. The docking scoring function, E score, 
is defined by the energy terms in equation 1 (see supplementary 
material). Re-rank-score in MVD provides an estimate for interaction. 
 
Discussion: 
Model evaluation: 
The constructed 3D model is shown in Figure 1. The results of 
PROCHECK parameters like Ramachandran plot (90.8 core, 7.7 
allowed, 1.1 generous, 0.4 disallowed), main chain (6), side chain (5), 
bond length (97.8), bond angle (93.4) and list of all planar groups 
(100) were within favorable limits for the constructed model. The 
folding patterns evaluated by WHAT CHECK is similar to the 
comparative study of various tools for secondary structure prediction 
(GOR, JFRED, HNN, NN predict, PORTER, SOPMA and SSpro). 
Therefore, the constructed model holds good for folding patterns. The 
RMSD value calculated for model backbone after first fit to backbone 
at 9000 cycles (9ps time) gave a constant deviation of 0.125 nm. 
RMSF value calculated for the model was between 0.025-0.125 nm. 
The RMSD and RMSF values calculated were within the favorable 
limit of 0.2 nm.  
 
Inhibition site: 
Literature studies have shown that phosporylation and consequently 
dephosphorylation brings about the activation of c-jun. The NH2 
terminal phosphorylation of c-jun in response to growth factors and 
UV rays is responsible for COOH terminal dephosphorylation. The 
NH2 terminal amino acid that undergoes phosphorylation is serine 63, 
serine 73 and threonine 91. This initiates dephosphorylation of 
residues threonine 231, serine 243 and serine 249. Dephosphorylation 
decreases the electrostatic repulsions between the phosphate groups on 
c-jun and the DNA-binding site, hence enhancing c-jun binding on 
DNA [9-11]. Hence, the 3 phosphorylation sites should be inhibited 
simultaneously in order to suppress the binding of c-jun on DNA and 
transcription of MMPs. 
 
Ligand Design: 
Novel ligands have been designed with ligand scout 2.02. The 
constructed ligand that showed interaction at desired phosphorylation 
inhibition sites by AUTODOCK were considered as reference ligand. 
We developed 3 reference ligands for the three inhibitory sites. Figure 
2 shows the interactions of the reference ligand at the desired site on 
receptor. The reference ligand for site 1 shows interaction with ser 63 
(desired) and asp 65. Similarly, reference ligand designed for site 2 
shows interaction with ser 73 (desired) and glu77. The reference 
ligand for site 3 shows interaction with ser 83, gly 86, his 87, thr 90 
and thr 91 (desired). The R1 symbol on each reference ligand identifies 
the site, where desired interaction is seen between ligand and receptor. 
All the three reference ligands interacted well at the desired sites for 
corresponding phosphorylation. 
 
Virtual screening: 
The reference ligands however showed desired interaction on receptor 
but have low binding affinity with the receptor as demonstrated by 
MVD. Various analogues have been constructed by adding different 
functional groups (from + inductive effect to –inductive effect) at the 
sites R1 and R2 to obtain ligands having greater binding affinity with 
the receptor. Additional functional groups at R1 increased the affinity 
of ligand at the desired inhibitory site. However, attachment of 
different functional groups at R2 created an environment by interacting 
with neighboring residues as shown in Figure 3. The designed 
analogues also gave better calculations for binding affinity, moldock 
score and re-ranking score than their corresponding reference ligands, 
listed in Table 2 (See supplementary material). Thus, the designed 
analogues showed interaction at desired inhibitory site with good 
docking score, for potential testing as a ligand.   
 
 
Figure 1: 3D model of c-jun. The model is generated using MODELLER.  Bioinformation   open access 
www.bioinformation.net    Hypothesis
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Figure 2: The docking view showing the binding of designed reference ligands with receptor at desired site. Bioinformation   open access 
www.bioinformation.net    Hypothesis
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Figure 3: The docking view of analogues and receptor for three different inhibition site. 
 
Conclusion: 
Wrinkle formation is one of the most prominent signs of skin ageing. 
There is a tremendous demand for products that can completely inhibit 
collagen degradation. However, these products have side effects. 
Therefore, it is important to design inhibitors for targets like c-jun that 
are associated with wrinkle formation. Here, we show the use of 
modeling and virtual screening in the potential design of inhibitors for 
c-jun. It should be noted that these predicted data should be validated 
using suitable assays for further consideration in future studies. 
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Supplementary material: 
 
E Score = E inter + E intra   __----------->    Equation 1 
   
 
 
Where EPLP is a piecewise linear potential and the second term describes the electrostatic interactions between charged atoms 
 
 
 
Where double summation is between all atom pairs in the ligand, the second term is a torsional energy, θ is the torsional angle of the bond and 
Eclash, assigns a penalty of 1000 if the distance between two heavy atoms is less than 2.0 A.  
 
Table 1:  List of PDB templates used for segment based homology modeling 
Segment based Homology Modeling 
Tools used/purpose  Selected 
templates 
         (PDB ID) 
Length covered by PDB template 
on the protein sequence 
Sequence/ fold identity between the PDB 
and reference protein sequence 
2AMI 1-5    100% 
2PZJ 6-17  66% 
1FCY 72-96  46% 
1AF2 173-204  40% 
1JNM 254-310  98% 
BLAST & PSI BLAST 
(Selection of PDB templates for 
model construction) 
1U7O 314-331  50% 
LOMETS 
(To fill the loops, regions not 
covered by BLAST PDB ) 
1ERD 
2FFT 
1DEV 
30-69 
97-170 
206-246 
 
> 50% 
 
Table 2: Comparative study of binding affinity, moldock score and re-ranking score of reference ligand with analogues for three inhibitory sites 
SITE I (ser 63) 
R1 R2  Binding  affinity  Moldock score  Reranking score 
O O  -12.2805 -87.5834 -72.9544 
COCl O  -16.5375 -111.701  -84.5607 
COCH3 O  -14.6547  -117.062  -83.3443 
OSO3H O  -13.0595  -120.418  -85.0854 
COOEt O  -16.4993  -120.514  -92.2664 
C6H5O O  -15.206  -122.575  -90.6628 
H2OPO2 O  -13.9347  -130.74  -98.4258 
C6H5OAc O  -16.7329  -134.646  -99.2073 
C6H5NO O  -14.3909  -130.665  -95.9775 
C6H5CHO O  -11.7646  -134.708  -90.5285 
C6H5OAc CHO  -20.9032  -120.961  -93.2101 
C6H5OAc COCH3  -19.8917  -143.012  -103.415 
C6H5OAc ONO  -24.7791 -142.664 -103.735 
C6H5OAc OCHO  -19.8626  -146.693  -98.6499 
C6H5OAc SO2H  -19.0394  -144.512  -103.86 
C6H5CHO COOCH3  -19.4519  -124.963  -96.1255 
C6H5CHO CONH2  -17.2812 -144.175 -110.27 
C6H5CHO COCl  -19.116  -120.203  -89.3363 
C6H5CHO NO  -17.9934  -135.044  -103.948 
C6H5CHO OAc  -19.905  -138.993  -105.387 
COPh CONH2  -15.1967 -138.589 -101.398 
COPh COCl  -18.0481  -145.42  -101.962 
COPh NHAc  -14.2186 -147.456 -107.879 
H2PO3 ONO  -15.8022  -121.942 -96.432 
H2PO3 NHAc  -14.8584 -125.068 -97.9593 
H2PO3 OAc  -20.6259  -128.349  -102.712 
H2PO3  COOCH3           -20.9547  -129.354  -101.996 Bioinformation   open access 
www.bioinformation.net    Hypothesis
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SITE II  (ser 73) 
R1  R2  Binding affinity  Moldock score  Reranking score 
O O  -10.0975 -97.968 -75.8075 
H2PO3 O  -12.601  -100.64  -87.7476 
NO  O  -12.4778 -110.199 -91.3151 
COOPh  O  -19.5081 -114.199 -96.0297 
OCH3 O -15.5548  -115.03  -93.0747 
OAc  O  -16.2034 -118.937 -94.9341 
C6H5COOCH3  O  -20.6526 -119.826 -94.7233 
C6H5OPO3H2  O  -20.0411 -105.614 -89.0779 
C6H5SO2H O  -17.75 -119.0791  -95.3803 
C6H5OCHO O  -20.1399 -124.793 -91.277 
C6H5CHO  O  -18.8208 -129.938 -102.681 
COOEt CHO -14.8759  -112.365  -93.4722 
COOEt    COCl  -19.3856 -109.854 -94.6401 
C6H5CHO  COOCH3  -24.4418 -116.134 -90.7422 
C6H5CHO            COCH3  -25.0494  -110.399  -77.1874 
C6H5CHO  COOEt  -24.4518 -109.6 -83.6871 
C6H5CHO CONH2  -22.3118 -107.413 -74.9499 
C6H5OCHO  CHO  -21.9882 -121.115 -93.1812 
C6H5OCHO  COOCH3  -27.3662 -116.949 -89.2061 
C6H5OCHO COCH3  -29.4138  -110.29  -75.225 
SITE III  (Thr 91) 
R1  Binding affinity  Moldock score  Reranking score 
O  -10.6525 -62.9956  -42.2497 
COOCH3 -13.8865  -93.0221  -70.5025 
COPh -12.9626  -86.2756  -66.2633 
ONO -14.2588  -93.4583 -70.182 
OAc -13.6479  -93.0005  -70.1516 
SO2H -10.0113  -93.6338  -68.6467 
NHAc -10.2655  -94.0558 -74.6504 
OSO3H -11.8516  -96.7543 -71.6728 
OPO3H2 -13.4183  -97.025  -68.2773 
C6H5CHO -11.9956  -98.2812  -74.4093 
C6H5NO -13.3098  -102.005  -73.7687 
C6H5COCH3 -13.6466  -102.861  -75.4764 
C6H5OAc -14.6636  -112.187  -83.7989 
C6H5COOCH3 -14.5597 -112.00  -78.0367 
COOPh -14.2241  -115.306 -83.0351 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 